Robert Lorne Hopfner, Director at Inozyme Pharma, Inc. (INZY), bought 689,184 shares at $4.54 ($3.1M) on 2023-03-29, disclosed to the SEC on 2023-03-30.
Open-market purchase of $3.1M INZY by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.54 | 344,592 | $1.6M | 50.0% |
| 2 | $4.54 | 344,592 | $1.6M | 50.0% |
| Total | $4.54 avg | 689,184 | $3.1M | 100% |
| Filing → |
| INZY | BUY | 2023-05-15 | $5.7M | — | Filing → |
| INZY | BUY | 2023-03-29 | $1.7M | — | Filing → |
| INZY | BUY | 2022-04-20 | $3.9M | — | Filing → |